Autoreactive Lymphocyte

Autoreactive Lymphocyte designates a B or T lymphocyte whose antigen receptor recognises self-antigens, potentially triggering autoimmune responses when central and peripheral tolerance mechanisms fail to eliminate or silence these potentially self-destructive immune cells. Under normal conditions, autoreactive lymphocytes are removed through clonal deletion or rendered non-responsive through anergy induction.

The biopharmaceutical industry targets autoreactive lymphocyte pathways in autoimmune disease treatment, developing therapies that selectively deplete pathogenic self-reactive clones, re-establish tolerance, or suppress autoreactive responses without compromising protective immunity. Biologics including anti-CD20 antibodies depleting B cells reduce autoantibody production in diseases like rheumatoid arthritis and lupus. Regulatory T cell-enhancing therapies aim to restore immunological self-tolerance. Antigen-specific tolerance induction approaches seek to selectively silence autoreactive clones recognising specific self-antigens. Understanding autoreactive lymphocyte escape mechanisms informs development of more targeted interventions addressing root causes of autoimmune pathology.